IL269187B2 - Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal - Google Patents

Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal

Info

Publication number
IL269187B2
IL269187B2 IL269187A IL26918719A IL269187B2 IL 269187 B2 IL269187 B2 IL 269187B2 IL 269187 A IL269187 A IL 269187A IL 26918719 A IL26918719 A IL 26918719A IL 269187 B2 IL269187 B2 IL 269187B2
Authority
IL
Israel
Prior art keywords
hippo
activates
muscle cell
cardiac muscle
cell renewal
Prior art date
Application number
IL269187A
Other languages
English (en)
Hebrew (he)
Other versions
IL269187B1 (en
IL269187A (en
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of IL269187A publication Critical patent/IL269187A/en
Publication of IL269187B1 publication Critical patent/IL269187B1/en
Publication of IL269187B2 publication Critical patent/IL269187B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
IL269187A 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal IL269187B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471204P 2017-03-14 2017-03-14
PCT/US2018/022496 WO2018170172A1 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal

Publications (3)

Publication Number Publication Date
IL269187A IL269187A (en) 2019-11-28
IL269187B1 IL269187B1 (en) 2023-12-01
IL269187B2 true IL269187B2 (en) 2024-04-01

Family

ID=63523973

Family Applications (2)

Application Number Title Priority Date Filing Date
IL269187A IL269187B2 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
IL308112A IL308112B2 (en) 2017-03-14 2018-03-14 A dominant active YAP gene, which activates HIPPO, induces chromatin accessibility and myocardial cell renewal

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL308112A IL308112B2 (en) 2017-03-14 2018-03-14 A dominant active YAP gene, which activates HIPPO, induces chromatin accessibility and myocardial cell renewal

Country Status (10)

Country Link
US (3) US11484553B2 (enExample)
EP (1) EP3595642A4 (enExample)
JP (3) JP2020513810A (enExample)
CN (2) CN110520112A (enExample)
AU (2) AU2018234632B2 (enExample)
BR (1) BR112019018912A2 (enExample)
CA (1) CA3056231A1 (enExample)
IL (2) IL269187B2 (enExample)
MX (2) MX2019010986A (enExample)
WO (1) WO2018170172A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018223062A1 (en) * 2017-06-01 2018-12-06 Baylor College Of Medicine Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
US11179479B2 (en) 2018-01-05 2021-11-23 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
WO2021119030A1 (en) * 2019-12-09 2021-06-17 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
US20210324412A1 (en) * 2020-04-15 2021-10-21 University Of Southern California Activation of yap signaling for sensory receptor regeneration
CN111778281B (zh) * 2020-07-17 2021-04-23 四川省人民医院 一种视网膜双极细胞病变模型的构建方法及其应用
US20230193267A1 (en) * 2021-10-19 2023-06-22 Animatus Biosciences, Inc. Cardiac cell proliferation by administering inhibitors of sav1, nf2, mob1 and/or mutant srf
WO2024168269A1 (en) * 2023-02-10 2024-08-15 Baylor College Of Medicine Use of mutant yap for improving cardiac function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
CA2110899C (en) 1991-06-21 2006-08-08 Jacob G. Michael Orally administrable therapeutic proteins and method of making
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
TW563139B (en) 2000-11-30 2003-11-21 Nec Tokin Corp Magnetic core including magnet for magnetic bias and inductor component using the same
US8140593B2 (en) * 2008-05-15 2012-03-20 Microsoft Corporation Data viewer management
KR101057116B1 (ko) 2008-06-17 2011-08-16 한국과학기술원 포유류에서의 분화 조절제 및 분화 조절 방법
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2015074010A2 (en) * 2013-11-18 2015-05-21 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN103705505A (zh) * 2013-12-19 2014-04-09 清华大学深圳研究生院 辛伐他汀的新用途
WO2015121323A1 (en) * 2014-02-11 2015-08-20 Institut Pasteur Treatment of cardiac diseases with modulators of the hippo pathway
WO2016044096A1 (en) * 2014-09-16 2016-03-24 Albert Einstein College Of Medicine Of Yeshiva University Repopulation of organs and tissues using a yap-ert2 fusion protein
GB201819659D0 (en) * 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HE, MINGJING, ET AL., NEW INSIGHTS INTO POSTTRANSLATIONAL MODIFICATIONS OF HIPPO PATHWAY IN CARCINOGENESIS AND THERAPEUTICS, 1 March 2016 (2016-03-01) *
LIN, ZHIQIANG, ET AL., CARDIAC-SPECIFIC YAP ACTIVATION IMPROVES CARDIAC FUNCTION AND SURVIVAL IN AN EXPERIMENTAL MURINE MI MODEL, 18 July 2014 (2014-07-18) *
VON GISE, ALEXANDER, ET AL., YAP1, THE NUCLEAR TARGET OF HIPPO SIGNALING, STIMULATES HEART GROWTH THROUGH CARDIOMYOCYTE PROLIFERATION BUT NOT HYPERTROPHY, 30 January 2012 (2012-01-30) *
XIAO, YANG, ET AL., HIPPO/YAP SIGNALING IN CARDIAC DEVELOPMENT AND REGENERATION, 4 April 2016 (2016-04-04) *
XIN, MEI, ET AL., HIPPO PATHWAY EFFECTOR YAP PROMOTES CARDIAC REGENERATION, 31 December 2013 (2013-12-31) *
ZHAO, BIN, ET AL., A COORDINATED PHOSPHORYLATION BY LATS AND CK1 REGULATES YAP STABILITY THROUGH SCF?-TRCP, 1 January 2010 (2010-01-01) *
ZHAO, BIN, ET AL., BOTH TEAD-BINDING AND WW DOMAINS ARE REQUIRED FOR THE GROWTH STIMULATION AND ONCOGENIC TRANSFORMATION ACTIVITY OF YES-ASSOCIATED PROTEIN, 20 January 2009 (2009-01-20) *

Also Published As

Publication number Publication date
CA3056231A1 (en) 2018-09-20
US12138284B2 (en) 2024-11-12
JP2020513810A (ja) 2020-05-21
US11484553B2 (en) 2022-11-01
JP2024073571A (ja) 2024-05-29
EP3595642A1 (en) 2020-01-22
IL308112A (en) 2023-12-01
AU2018234632B2 (en) 2024-06-13
WO2018170172A1 (en) 2018-09-20
AU2024219497B2 (en) 2025-08-14
US20230063735A1 (en) 2023-03-02
CN110520112A (zh) 2019-11-29
JP2022164658A (ja) 2022-10-27
MX2022011881A (es) 2022-11-09
IL308112B1 (en) 2024-09-01
AU2018234632A1 (en) 2019-10-03
IL269187B1 (en) 2023-12-01
JP7461071B2 (ja) 2024-04-03
BR112019018912A2 (pt) 2020-04-14
US20200016212A1 (en) 2020-01-16
AU2024219497A1 (en) 2024-10-03
IL269187A (en) 2019-11-28
MX2019010986A (es) 2020-02-05
CN116003564A (zh) 2023-04-25
US20250073276A1 (en) 2025-03-06
IL308112B2 (en) 2025-01-01
EP3595642A4 (en) 2021-05-26

Similar Documents

Publication Publication Date Title
IL269187B2 (en) Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
Braun et al. Dichotomous function of IL-33 in health and disease: from biology to clinical implications
WO2019191341A8 (en) Nucleic acid-based therapeutics
WO2019126634A3 (en) Targeted integration of nucleic acids
TN2019000122A1 (en) Method for increasing the secretion levels of interleukin 2 and proteins derived from it
EP4249036A3 (en) Methods and products for nucleic acid production and delivery
MX2016005101A (es) Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
CA2851316C (en) Genes and proteins for alkanoyl-coa synthesis
WO2015048348A3 (en) Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof
WO2016201380A8 (en) Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2014164348A3 (en) Modified caspase polypeptides and uses thereof
JP2015134796A5 (enExample)
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2015158808A3 (en) Recombinant host cell engineered to overexpress helper proteins
EP3943092A3 (en) Compositions for use in inducing differentiation of human brown adipocyte progenitors
WO2014151683A8 (en) Gla domains as therapeutic agents
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
JP2015511599A5 (enExample)
IN2014DN06920A (enExample)
BR112013018744A2 (pt) método para produzir um polipetídeo ou uma proteína recombinante
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
WO2016100820A3 (en) Fgf2 truncations and mutants and uses thereof
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins